Search over 3,000 reports

    Traumatic Brain Injury(TBI) - Pipeline Insights, 2017

    Traumatic Brain Injury(TBI) - Pipeline Insights, 2017
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 156
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIPI0149
    DelveInsight's, "Traumatic Brain Injury-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Traumatic Brain Injury. This report provides information on the therapeutic development based on the Traumatic Brain Injury dealing with all the pipeline drugs, comparative analysis of Traumatic Brain Injury at various stages covering Phase III, Phase II, Phase I, IND, Pre-clinical, and Discovery stages therapeutics assessment by monotherapy products and molecule type drug information. The report also covers the company's information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
    Introduction
    Overview
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Late Stage Products (Phase III)
    Mid Stage Products (Phase II)
    Early Stage Products (Phase I and IND)
    Pre-clinical and Discovery Products
    Therapeutic Assessment: Active Products
    Dormant Products
    Discontinued Products
    Comparative Analysis
    Companies involved in Therapeutic Development
    Appendix
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Table 1: Number of Products Under Development for Traumatic Brain Injury
    Table 2: Number of Products under Development by Companies
    Table 3: Late Stage Products (Phase III)
    Table 4: Mid Stage Products (Phase II)
    Table 5: Early Stage Products (Phase I and IND)
    Table 6: Pre-clinical Products
    Table 7: Discovery Products
    Table 8: Assessment by Monotherapy Products
    Table 9: Assessment by Combination Therapy Products
    Table 10: Assessment by Route Of Administration
    Table 11:Assessment by Stage and Route Of Administration
    Table 12: Assessment by Molecule Type
    Table 13: Assessment by Stage and Molecule Type
    Table 14: Dormant Products
    Table 15: Discontinued Products
    Table 16: American Life Science Pharmaceuticals (ALSP), Overview
    Table 17: Anvyl LLC, Overview
    Table 18: Apollo Endosurgery, Overview
    Table 19: Aptinyx, Overview
    Table 20: Astrocyte Pharmaceuticals Inc., Overview
    Table 21: Athersys, Overview
    Table Continued?
    Table 56: VG Life Sciences, Overview
    Figure 1: Symptoms of Traumatic Brain Injury
    Figure 2:Number of Products under Development for Traumatic Brain Injury,2017
    Figure 3: Late Stage Products (Phase III)
    Figure 4: Mid Stage Products (Phase II)
    Figure 5: Early Stage Products (Phase I and IND)
    Figure 6: Pre-clinical and Discovery Products
    Figure 7: Assessment by Monotherapy Products
    Figure 8: Assessment by Combination Therapy Products
    Figure 9: Assessment by Route of Administration
    Figure 10: Assessment by Stage and Route of Administration
    Figure 11: Assessment by Molecule Type
    Figure 12: Assessment by Stage and Molecule Type
    Figure 13: Dormant Products
    Figure 14: Discontinued Products
    Traumatic Brain Injury(TBI) Pipeline Drugs

    Traumatic Brain Injury(TBI) Pipeline Assessment

    Traumatic Brain Injury(TBI) Pipeline Analysis

    Traumatic Brain Injury(TBI) Drugs under Development

    Traumatic Brain Injury(TBI) Discovery drugs

    Traumatic Brain Injury(TBI) Preclinical drugs

    Traumatic Brain Injury(TBI) Phase I drugs

    Traumatic Brain Injury(TBI) Phase II drugs

    Traumatic Brain Injury(TBI) Phase III Pipeline Drugs Assessment

    Traumatic Brain Injury(TBI) Preregistration drugs

    Traumatic Brain Injury(TBI) Molecules in pipeline

    • Single User License
      (20% Off)
      $2,000.00
      $1600
    • Site License
      (30% Off)
      $4,000.00
      $2800
    • Global License
      (40% Off)
      $6,000.00
      $3600

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap